Urinary F2-isoprostanes are not associated with increased risk of type 2 diabetes

35Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

Objective: Free radicals have been implicated in the etiology of type 2 diabetes. Cross-sectional studies have demonstrated associations between oxidative damage and type 2 diabetes. However, no prospective data on this association are available. Research Methods and Procedures: A case control study was conducted within the prospective cohort of the Insulin Resistance Atherosclerosis Study: 26 cases who developed type 2 diabetes in the follow-up period and 26 controls who remained free of type 2 diabetes were randomly selected. Oxidative status was assessed by measuring 2,3-dinor-5,6-dihydro-15- F2t-isoprostane (F2-IsoPM) in baseline urine samples using gas chromatography/mass spectroscopy. Type 2 diabetes was defined by serial oral glucose tolerance tests and World Health Organization criteria. Results: Urinary F2-IsoPM varied between 0.18 and 2.60 ng/mg creatinine; 25th/50th/75th percentiles were 0.42, 0.60, and 0.89, respectively. A trend toward higher levels were observed in women and in persons with impaired glucose tolerance at baseline (p = 0.1). F2-IsoPM increased with BMI (r = 0.36, p = 0.01). After adjustment for age, gender, baseline impaired glucose tolerance status, and BMI, F2-IsoPM levels were inversely associated with development of type 2 diabetes: odds ratio = 0.32 (95% confidence interval, 0.12 to 0.81) for the difference between the 75th and 25th percentiles. Discussion: These results suggest that oxidative damage is not a cause of type 2 diabetes. Positive cross-sectional associations of F2-IsoPM with the risk factors for diabetes. BMI, and impaired glucose tolerance and inverse associations with development of type 2 diabetes indicate that F 2-IsoPM might reflect a compensatory mechanism. Copyright © 2005 NAASO.

Cite

CITATION STYLE

APA

Il’yasova, D., Morrow, J. D., & Wagenknecht, L. E. (2005). Urinary F2-isoprostanes are not associated with increased risk of type 2 diabetes. Obesity Research, 13(9), 1638–1644. https://doi.org/10.1038/oby.2005.201

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free